Management of pulmonary toxicity associated with targeted anticancer therapies

Bibliography

• Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18
   PubMed Web of Science ®Google Scholar
• Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: a review. Target Oncol 2011;6:235-43
   PubMed Web of Science ®Google Scholar
• Brandes AA, Bartolotti M, Tosoni A, et al. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 2015;20:166-75
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEJM 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133:528-38
   PubMed Web of Science ®Google Scholar
• Reck M, Barlesi F, Crinò L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012;23:1111-20
   PubMed Web of Science ®Google Scholar
• Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010;11:733-40
   PubMed Web of Science ®Google Scholar
• Shamloo BK, Chhabra P, Freedman AN, et al. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf 2012;35:507-18
   PubMed Web of Science ®Google Scholar
• Lind JSW, Senan S, Smit EF. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J Clin Onc 2012;30:e104-8
   PubMed Web of Science ®Google Scholar
• Seidel C, Janssen S, Karstens JH, et al. Recall pneumonitis during systemic treatment with sunitinib. Ann Oncol 2010;21:2119-20
   PubMed Web of Science ®Google Scholar
• Yuasa T, Kitsukawa S, Sukegawa G, et al. Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer 2013;13:3
   PubMed Web of Science ®Google Scholar
• Boyle HJ, Chatté G, Rivoire M, Fléchon A. Lung toxicity in a patient treated with sunitinib. Eur Respir J 2012;40:1300-3
   PubMed Web of Science ®Google Scholar
• Kushima H, Ishii H, Kadota J. Sunitinib-related interstitial pneumonia after treatment with temsirolimus: a case of possible recall phenomenon. Int J Urol 2014;21:420-1
   PubMed Web of Science ®Google Scholar
• Katta A, Fesler MJ, Tan A, et al. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy. Cancer Chemother Pharmacol 2010;66:409-12
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17
   PubMed Web of Science ®Google Scholar
• Iavarone M, Cabibbo G, Piscaglia F, et al. SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 2011;54:2055-63
   PubMed Web of Science ®Google Scholar
• Blumenschein G, Saintigny P, Liu S, et al. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 2013;19:6967-75
   PubMed Web of Science ®Google Scholar
• Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113
   PubMed Web of Science ®Google Scholar
• Hutson TE, Bellmunt J, Porta C, et al. Sorafenib TARGET Clinical Trial Group. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46:2432-40
   PubMed Web of Science ®Google Scholar
• Ide S, Soda H, Hakariya T, et al. Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event. Lung Cancer 2010;67:248-50
   PubMed Web of Science ®Google Scholar
• Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol 2013;18:743-9
   PubMed Web of Science ®Google Scholar
• Van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo- controlled phase 3 trial. Lancet 2012;379:1879-86
   PubMed Web of Science ®Google Scholar
• Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001;61:58-66
   PubMed Web of Science ®Google Scholar
• Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014;6:CD006242
   PubMed Web of Science ®Google Scholar
• Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. Respirology 2006;11:655-8
   PubMed Web of Science ®Google Scholar
• Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003;21:552-5
   PubMed Web of Science ®Google Scholar
• Pepels MJ, Boomars KA, Van Kimmenade R, Hupperets PS. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat 2009;113:609-12
   PubMed Web of Science ®Google Scholar
• Diéras V, Harbeck N, Budd GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 2014;32:2750-7
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim SB, González-Martín A, et al. TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99
   PubMed Web of Science ®Google Scholar
• Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007;13:6175-81
   PubMed Web of Science ®Google Scholar
• Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015;33:442-7
   PubMed Web of Science ®Google Scholar
• Miller KD, Diéras V, Harbeck N, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol 2014;32:1437-44
   PubMed Web of Science ®Google Scholar
• Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-600
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(1):25-32
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
   PubMed Web of Science ®Google Scholar
• Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-7
   PubMed Web of Science ®Google Scholar
• Albanell J, Montagut C, Jones ET, et al. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 2008;14:2726-231
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9
   PubMed Web of Science ®Google Scholar
• Chua W, Peters M, Loneragan R, Clarke S. Cetuximab-associated pulmonary toxicity. Clin Colorectal Cancer 2009;8:118-20
   PubMed Web of Science ®Google Scholar
• Hughes S, Liong J, Miah A, et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 2008;3:648-51
   PubMed Web of Science ®Google Scholar
• De Vos FY, Driessen CM, Jaspers HC, et al. Cetuximab-induced pneumonitis in head and neck cancer patient. Oral Oncol 2012;48:e17-18
   PubMedGoogle Scholar
• Achermann Y, Frauenfelder T, Obrist S, et al. A rare but severe pulmonary side effect of cetuximab in two patients. BMJ Case Rep 2012;2012
   Google Scholar
• Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15:569-79
   PubMed Web of Science ®Google Scholar
• Tang NP, Li H, Qiu YL, et al. Risk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials. Tumour Biol 2014;35:10409-18
   PubMed Web of Science ®Google Scholar
• Wu M, Rivkin A, Pham T. Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther 2008;30:14-30
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Borgonovo K, Barni S. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol 2012;23:1672-9
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, et al. FDA drug aproval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist 2003;8:303-6
   PubMed Web of Science ®Google Scholar
• Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Lung Cancer 2014;83:231-9
   PubMed Web of Science ®Google Scholar
• Inoue A, Xin H, Suzuki T, et al. Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. Cancer Sci 2008;99:1679-84
   PubMed Web of Science ®Google Scholar
• Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008;177:1348
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56
   PubMed Web of Science ®Google Scholar
• Hotta K, Kiura K, Tabata M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-24
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung cancer 2004;45:93-104
   PubMed Web of Science ®Google Scholar
• Min JH, Lee HY, Lim H, et al. Drug induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 2011;68:1099-109
   PubMed Web of Science ®Google Scholar
• Togashi Y, Masago K, Hamatani Y, et al. Succesful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature. Lung Cancer 2012;77:464-8
   PubMed Web of Science ®Google Scholar
• Arakawa N, Tsujita A, Saito N, et al. Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases. Respirology Case Reports 2013;1:17-19
   PubMedGoogle Scholar
• Nakamichi S, Kubota K, Horinouchi H, et al. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. Jpn J Clin Oncol 2013;43:422-5
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2012;31:3327-34
   Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus Cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-22
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitnib, or both, and one or two lines of chemotherapy (LUX-lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
   PubMed Web of Science ®Google Scholar
• Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2012;134:1149-59
   PubMed Web of Science ®Google Scholar
• Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008;26:2999-3005
   PubMed Web of Science ®Google Scholar
• Burris HAIII, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13
   PubMed Web of Science ®Google Scholar
• Burris HA, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 2009;15:6702-8
   PubMed Web of Science ®Google Scholar
• Capri G, Chang J, Chen SC, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010;21:474-80
   PubMed Web of Science ®Google Scholar
• Rituximab FDA approval letter. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist [Last accessed 21 March 2015]
   Google Scholar
• Krishnaswamy U, Maka V, Subramanian M, et al. Rituximab induced interstitial lung disease in patients with Non-Hodgkin’s lymphoma: a clinical study of six cases and review of the literature. Lymphoma 2014;2014:6 Article ID 160421
   Google Scholar
• Lioté H, Lioté F, Séroussi B, et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010;35:681-7
   PubMed Web of Science ®Google Scholar
• Ghesquières H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005;16:1399
   PubMed Web of Science ®Google Scholar
• Salmasi G, Li M, Balasundaram S, et al. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab. Leuk Lymphoma 2014;1-19
   Google Scholar
• Andreas V, Muhammad K, Helen P, et al. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology 2012;51:653-62
   PubMed Web of Science ®Google Scholar
• Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008;49(9):1778-83
   PubMed Web of Science ®Google Scholar
• Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Onc 2014;11:24-37
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Can Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar
• Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014;74:1993-2013
   PubMed Web of Science ®Google Scholar
• Chow LQ. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book 2013
   PubMedGoogle Scholar
• Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 2012;30:2691-7
   PubMed Web of Science ®Google Scholar
• Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013;18:733-43
   PubMed Web of Science ®Google Scholar
• Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti–cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-32
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 2015;385-4):1-6
   PubMedGoogle Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-19
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368(25):2385-94
   PubMed Web of Science ®Google Scholar
• Tmiya A, Okamoto I, Miyazaki M, et al. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4- ALK–positive non–small-cell lung cancer. J Clin Oncol 2013;31(1):15-17
   Web of Science ®Google Scholar
• Ono A, Takahashi T, Oishi T, et al. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31(26):417-19
   Web of Science ®Google Scholar
• Watanabe N, Nakahara Y, Taniguchi H, et al. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia. Acta Oncol 2014;53:158-60
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Moro-Sibilot D, Gautschi O, et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer 2015;87:89-95
   PubMed Web of Science ®Google Scholar
• Rothenstein JM, Letarte N. Managing treatment–related adverse events associated with Alk inhibitors. Curr Oncol 2014;21:19-26
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc EU Xalkori (crizotinib) summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/002489/WC500134759.pdf [Last accessed 28 Febrauary 15]
   Google Scholar
• Shaw A, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 2014;370:1189-97
   PubMed Web of Science ®Google Scholar
• Asai N, Yamaguchi E, Kubo A. Successful crizotinib rechallegne after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2014;15:e33-5
   PubMedGoogle Scholar
• Yanagisawa S, Inoue A, Koarai A, et al. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. J Thorac Oncol 2013;8(8):e73-4
   PubMedGoogle Scholar
• Tachihara M, Kobayashi K, Ishikawa Y, et al. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease. Jpn J Clin Oncol 2014;44:762-4
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely G, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28
   PubMed Web of Science ®Google Scholar
• Gettinger S, Bazhenova L, Salgia R, et al. ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ nong-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol 2014;25(Suppl 4):iv426-70
   Google Scholar
• Gartrell B, Ying J, Sivendran S, et al. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Targ Oncol 2014;9:195-204
   PubMed Web of Science ®Google Scholar
• Albiges L, Chamming’s F, Duclos B, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;1-11
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Atkinson B, Cauley D, Chaan NG, et al. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 2014;113:376-82
   PubMed Web of Science ®Google Scholar
• Dabydeen DA, Jagannathan JP, Ramaiya N, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence radiographic findings and correlation with clinical outcome. Eur J Cancer 2012;48:1519-24
   PubMed Web of Science ®Google Scholar
• Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-99
   PubMed Web of Science ®Google Scholar
• White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J respir Crit Care Med 2012;182:396-403
   Web of Science ®Google Scholar